Pi-Sunyer X. The Medical Risks of Obesity. Postgrad Med 009;121:21-33.
Carneiro G, Zanella MT. Obesity metabolic and hormonal disorders associated with obstructive sleep apnea and their impact on the risk of cardiovascular events. Metabolism. 018;84:76-84.
Prenner SB, Mather PJ. Obesity and heart failure with preserved ejection fraction: A growing problem. Trends Cardiovasc Med. 2018;28:322-327.
Himbert C, Delphan M, Scherer D, et al. Signals from the adipose microenvironment and the obesity-cancer link-a systematic review. Cancer Prev Res (Phila). 2017;10: 494-506.
Gorodner V, Viscido G2, Signorini F, et al. Gastroesophageal reflux disease and morbid obesity: evaluation and treatment. Updates Surg. 2018 ;70(3):331-337.
Mahmoudian A, van Assche D, Herzog W, et al. Towards secondary prevention of early knee osteoarthritis. RMD Open. 018;4:e000468.
Cuomo A, Bolognesi S, Goracci A, et al. Feasibility, adherence and efficacy of liraglutide treatment in a sample of individuals with mood disorders and obesity. Front Psychitr. 2019; 9:784.
Prospective Studies Collaboration. Body-mass index and cause-specific mortality in 900,000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373:1083-1096.
Salvestrini V, Sell C, Lorenzini A. Obesity may accelerate the aging process. Front Endocrinol (Lausanne).019;10:266.
Goosens GH. The metabolic phenotype in obesity: fat mass, body fat distribution, and adipose tissue function. Obes Facts. 017;10:207-215.
EASO Patient Council. Five key propositions for GPs. Available at: https://easo.org/education/guidelines/. Accessed May 3, 2019.
Park J, Morley TS, Kim M, et al. Obesity and cancer—mechanisms underlying tumour progression and recurrence. Nat Rev Endocrinol. 2014;10:455-465.
Knowler WC, Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
Li G, Zhang P, Wang J, et al. Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study. Lancet Diabetes Endocrinol. 2014;2:474-480.
Ryan DH, Yockey SR. Weight loss and improvement in comorbidity: differences at 5%, 10%, 15%, and over. Curr Obes Rep. 2017;6:187-194.
Wing RR, Lang W, Wadden TA, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34:1481-1486.
Foster GD, Borradaile KE, Sanders MH, et al. A randomized study on the effect of weight loss on obstructive sleep apnea among obese patients with type 2 diabetes: The Sleep AHEAD Study. Arch Intern Med 2009;169:1619-1626.
Warkentin LM, Majumdar SR, Johnson JJ, et al. Predictors of health-related quality of life in 500 severely obese patients. Obes Rev. 2014;15:169-182.
Sumithran P, Prendergast LA, Delbridge E, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365:1597-1604.
Muller MJ, Bosy-Westphal A, Heymsfield SE. Is there evidence for a set point that regulates human body weight? F1000 Medicine Reports. 2010;2:59.
Lean MEJ, Malkova D. Altered gut and adipose tissue hormones in overweight and obese individuals: cause or consequence? Int J Obes (Lond). 2016;40:622-632.
Melby CL, Paris HL, Foright RM, et al. Attenuating the biologic drive for weight regain following weight loss: must what goes down always go back up? Nutrients. 2017;9:468.
Mannan M, Mamun A, Doi S, et al. Prospective Associations between Depression and Obesity for Adolescent Males and Females- A Systematic Review and Meta-Analysis of Longitudinal Studies. PLos One. 2016;2016;11:e0157240.
Vallis M, Piccinini-Vallis H, Sharma AM, et al. Modified 5 As: Minimal intervention for obesity counseling in primary care. Can Fam Physician. 2013;59:27-31.
Gudzune KA, Bennet WL, Cooper LA, et al. Patients who feel judged about their weight have lower trust in their primary care providers. Patient Educ Couns. 2014;97:128-131.
Shibuya K, Pantalone KM, Burguera B. Obesity: Are shared medical appointments part of the answer? Cleve Clin J Med. 2018;85:699-706.
Xenical Package Insert. FDA.gov. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020766s026lbl.pdf. Accessed 7/19/19.
Saxenda Package insert. novo-pi.com. Available at: https://www.novo-pi.com/saxenda.pdf. Accessed 7/19/19.
Contrave Package Insert. contrave.com. Available at: https://contrave.com/content/pdf/Contrave_PI.pdf. Accessed 7/19/19.
Sjöström L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet. 1998;352:167-172.
Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond). 013;37:1443-1451.
Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376:595-605.
Sjöström L, Narbo K, Sjöström CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Eng J Med. 007;357:741-752.
Weng TC, Chang CH, Dong YH, et al. Anaemia and related nutrient deficiencies after Roux-en-Y gastric bypass surgery: a systematic review and meta-analysis. BMJ Open. 015;5:e006964.

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.

Moderator

Luc Van Gaal, MD, PhD

Emeritus Professor in Medicine
Consultant at Department Endocrinology, Diabetology
Antwerp University Hospital
Antwerp, Belgium

Disclosures

Disclosure: Luc Van Gaal, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Janssen Pharmaceuticals; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Merck & Co., Inc.; Mundipharma; Novo Nordisk; Sanofi; SERVIER/Intarcia Therapeutics, Inc.
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Janssen Pharmaceuticals; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Merck & Co., Inc.; Mundipharma; Novo Nordisk; Sanofi; SERVIER/Intarcia Therapeutics, Inc.

Faculty

Cathy Breen, RD, PhD

Weight Management & Diabetes Services
St Columcille's Hospital
Loughlinstown, Co Dublin, Ireland

Disclosures

Disclosure: Cathy Breen, RD, PhD, has disclosed the following relevant financial relationships:
Served as a speaker or a member of a speakers bureau for: Eli Lilly and Company; Janssen Pharmaceuticals; Merck Sharp & Dohme; Sanofi

Luca Busetto, MD

Associate Professor of Internal Medicine
Department of Medical and Surgical Sciences
University of Padova
Padova, Italy

Disclosures

Disclosure: Luca Basetto, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Novo Nordisk
Served as a speaker or a member of a speakers bureau for: Bruno Famacutici
Received grants for clinical research from: Enzyme Management

Rachel Pryke, MBBS, MRCGP, FRCP

GP and Trainer
Chair GPING (GPs with an Interest in Nutrition Group)
GP representative Obesity Health Alliance
Winyates Health Centre
Worcestershire, United Kingdom

Disclosures

Disclosure: Rachel Pyrke, MBBS, MRCGP, FRCP, has disclosed the following relevant financial relationships:
Served as a speaker or a member of a speakers bureau for: Novo Nordisk Special Instructions for EBAC programs or faculty from Johns Hopkins University or Emory University/Healthcare: Special disclosure language or disclaimer statements must be used (EBAC: place BEFORE authors; JHU and Emory place statement AFTER faculty affiliation and BEFORE disclosure information):

Editor

Robert McCarthy, PhD

Medical Education Director, WebMD Global, LLC

Disclosures

Disclosure: Robert McCarthy, PhD, has disclosed no relevant financial relationships.

Content Reviewer

Nafeez Zawahir, MD

Associate CME Clinical DirectorMedscape, LLC

Disclosures

Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.

CPD

Embracing Obesity in Collaboration – Why, When, and How to Intervene?

Authors: Luc Van Gaal, MD, PhD; Luca Busetto, MD; Rachel Pryke, MBBS, MRCGP, FRCP; Cathy Breen, BSc
CPD Released: 9/9/2019
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 9/9/2020, 11:59 PM EST

Start Activity

Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US primary care physicians, diabetologists & endocrinologists, and cardiologists.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Physiology and complexity of obesity as a chronic disease requiring long-term treatment
- Enduring weight loss achievable via a collaborative and integrated approach
- Concrete health benefits of moderate but sustained weight loss
Have greater competence related to
- Selecting appropriate evidence-based pharmacotherapy for sustained weight loss

Disclosures

Moderator

Luc Van Gaal, MD, PhD

Emeritus Professor in Medicine
Consultant at Department Endocrinology, Diabetology
Antwerp University Hospital
Antwerp, Belgium

Disclosures

Disclosure: Luc Van Gaal, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Janssen Pharmaceuticals; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Merck & Co., Inc.; Mundipharma; Novo Nordisk; Sanofi; SERVIER/Intarcia Therapeutics, Inc.
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Janssen Pharmaceuticals; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Merck & Co., Inc.; Mundipharma; Novo Nordisk; Sanofi; SERVIER/Intarcia Therapeutics, Inc.

Faculty

Cathy Breen, RD, PhD

Weight Management & Diabetes Services
St Columcille's Hospital
Loughlinstown, Co Dublin, Ireland

Disclosures

Disclosure: Cathy Breen, RD, PhD, has disclosed the following relevant financial relationships:
Served as a speaker or a member of a speakers bureau for: Eli Lilly and Company; Janssen Pharmaceuticals; Merck Sharp & Dohme; Sanofi

Luca Busetto, MD

Associate Professor of Internal Medicine
Department of Medical and Surgical Sciences
University of Padova
Padova, Italy

Disclosures

Disclosure: Luca Basetto, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Novo Nordisk
Served as a speaker or a member of a speakers bureau for: Bruno Famacutici
Received grants for clinical research from: Enzyme Management

Rachel Pryke, MBBS, MRCGP, FRCP

GP and Trainer
Chair GPING (GPs with an Interest in Nutrition Group)
GP representative Obesity Health Alliance
Winyates Health Centre
Worcestershire, United Kingdom

Disclosures

Disclosure: Rachel Pyrke, MBBS, MRCGP, FRCP, has disclosed the following relevant financial relationships:
Served as a speaker or a member of a speakers bureau for: Novo Nordisk Special Instructions for EBAC programs or faculty from Johns Hopkins University or Emory University/Healthcare: Special disclosure language or disclaimer statements must be used (EBAC: place BEFORE authors; JHU and Emory place statement AFTER faculty affiliation and BEFORE disclosure information):

Editor

Robert McCarthy, PhD

Medical Education Director, WebMD Global, LLC

Disclosures

Disclosure: Robert McCarthy, PhD, has disclosed no relevant financial relationships.

Content Reviewer

Nafeez Zawahir, MD

Associate CME Clinical DirectorMedscape, LLC

Disclosures

Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.

Accreditation Statements

Developed through a partnership between Medscape, World Obesity Federation, and World Organisation of Family Doctors.

For Physicians

The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional developmentcredits (CPD).

SCOPE Certification via Medscape and SCOPE E-Learning

To obtain credit towards SCOPE Certification please email [email protected].
For more information visit www.worldobesity.org/training-and-events/training/scope/certification

To qualify for SCOPE Certification, you will need to accrue a total of 12 SCOPE points, including 4 earned by completing the SCOPE Core Learning Path. You will also need to show evidence of having at least six months’ clinical experience managing patients with overweight or obesity.

The following steps outline one route by which a healthcare professional can apply for SCOPE Certification by combining Medscape CME activities with SCOPE E-Learning modules.

All SCOPE E-Learning modules referred to below can be accessed via www.scope-elearning.org. The Core Learning Path can be accessed for £70 (with discounts available for World Obesity members and HCPs in low-and-middle income countries) and all other modules are available for free.

Step 1: Complete the SCOPE Core Learning Path

= 4 SCOPE points

Step 2: Complete the following SCOPE Accredited Medscape activities below are the programs in this year’s initiative:
1. Embracing Obesity in Collaboration – Why, When & How to Intervene? (0.5 SCOPE points)
2. Are We Ready to Tackle Chronic Obesity in Primary Care? (0.5 SCOPE points)
3. In Dialogue with the Patient with Persistent Obesity – Proven Steps to Sustained Weight Loss (0.5 SCOPE points)
4. Enduring Obesity – Long-term Strategies for a Chronic Disease (0.5 SCOPE points)
= 2.0 SCOPE points

Step 3: Complete 12 free supplementary SCOPE E-Learning modules (0.5 SCOPE points each)

= 6.0 SCOPE

You will now have the 12 SCOPE points required for SCOPE Certification.

Step 4: Email [email protected] with evidence of your clinical experience. Your application will be reviewed. Subject to approval, your SCOPE Certification will be awarded within seven working days.

Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

From Medscape Education

CPD

Embracing Obesity in Collaboration – Why, When, and How to Intervene?

Authors: Luc Van Gaal, MD, PhD; Luca Busetto, MD; Rachel Pryke, MBBS, MRCGP, FRCP; Cathy Breen, BScFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CPD Released: 9/9/2019

Valid for credit through: 9/9/2020, 11:59 PM EST

processing....

Educational Impact Challenge

The goal of this activity is to improve/maintain physician competency in the management of obesity including unmet patient needs and the application of new treatment paradigms, and to increase awareness of emerging data on new therapeutic options. Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

Page 1 of 4

CPD Information Download Slides

Additional Resources

Expert Commentary

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been authorized by the European Medicines Agency for use in Europe, off-label uses of authorized products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

References

Faculty and Disclosures

Moderator

Luc Van Gaal, MD, PhD

Faculty

Cathy Breen, RD, PhD

Luca Busetto, MD

Rachel Pryke, MBBS, MRCGP, FRCP

Editor

Robert McCarthy, PhD

Content Reviewer

Nafeez Zawahir, MD

CPD

Embracing Obesity in Collaboration – Why, When, and How to Intervene?

Target Audience and Goal Statement

Disclosures

Moderator

Luc Van Gaal, MD, PhD

Faculty

Cathy Breen, RD, PhD

Luca Busetto, MD

Rachel Pryke, MBBS, MRCGP, FRCP

Editor

Robert McCarthy, PhD

Content Reviewer

Nafeez Zawahir, MD

Accreditation Statements

For Physicians

SCOPE Certification via Medscape and SCOPE E-Learning

Instructions for Participation and Credit

Embracing Obesity in Collaboration – Why, When, and How to Intervene?

Educational Impact Challenge

Expert Commentary